BioNTech (NASDAQ:BNTX) has been analyzed by 12 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish. The table below provides a concise overview of ...

・Kursplus von 0,67 Prozent zum Vortag bei Biontech-Aktie ・0,65 Prozent Plus zur Vorwoche ・Gegenüber dem Vorjahr stieg der Kurs um 23,94 Prozent. Die Aktie von Biontech sank gegenüber dem Vortag um ...

Insider trading activity involves company insiders, such as executives, directors, and employees, engaging in transactions of their own company's stock. Insiders' buy and sell transactions provide ...

BioNTech SE (NASDAQ:BNTX) is one of the Stocks That Will Go To The Moon in 2026. On December 18, BioNTech SE (NASDAQ:BNTX) announced the closing of its acquisition of CureVac N.V. (NASDAQ:CVAC), which ...

© Foto: Chris Emil Janssen - chris.emil-janssen.deDer Rückzug der mRNA-Pioniere ließ Milliarden an Börsenwert verdampfen. Einige Analysten halten die BioNTech-Aktie nach dem Schock aber plötzlich für ...

Vom jahrzehntelangen mRNA-Forschungsansatz über den pandemiebedingten Durchbruch bis zur strategischen Neuausrichtung als breit aufgestelltes Biotech-Unternehmen: Die Entwicklung von BioNTech zeigt, ...

BioNTech SE (NASDAQ:BNTX) is one of the best healthcare stocks to buy with highest upside potential. BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Company announced on May 30 interim Phase 2 data ...

MAINZ, Germany, October 22, 2025 (GLOBE NEWSWIRE) -- BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced it had commenced its public exchange offer (the “Offer”) for all outstanding shares of ...

High-rolling investors have positioned themselves bullish on BioNTech (NASDAQ:BNTX), and it's important for retail traders to take note. \This activity came to our attention today through Benzinga's ...

MAINZ, Germany, March 11, 2024 – BioNTech SE (BNTX) (Nasdaq: BNTX, “BioNTech” or “the Company”) will present clinical trial data for selected candidates from its oncology pipeline at the American ...